financetom
Business
financetom
/
Business
/
Ather Energy partially absorbs subsidy loss per scooter, targets offset in 18 months
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ather Energy partially absorbs subsidy loss per scooter, targets offset in 18 months
Jun 2, 2023 10:52 AM

After suffering a subsidy loss of Rs 32,000 per unit, electric scooter brand Ather Energy has partially absorbed some part of the subsidy loss and has passed on the rest of the burden to its consumers. The decision was based on the company's profitability per individual product and the subsequent possibility of absorbing the respective loss.

Share Market Live

NSE

The company has raised the price of its flagship product by Rs 7,000. Chief Business Officer at Ather Energy, Ravneet Phokela told CNBC TV18 that the price hike didn't impact its top product materially but the price of its entry level product has gone up by Rs 25,000 - Rs 30,000.

On the issue about whether the price hike will reduce EV adoption across the industry, Phokela said, "It will be easier for the market to accept and absorb changes from a short term hit and the hike is across the industry". He added that in the medium to long term he doesn't see the market changing dramatically, though in the next 3-4 months there may be a 15 percent-20 percent drop in demand.

Following complaints of overpricing, Ather Energy gave an undertaking to the Ministry of Heavy Industries that it will refund Rs 140 crores to customers who bought the charger separately. Phokela said that the company will take around 6 months to fully refund its customers and while 140 crores is an "unplanned & significant cost", the refund will not impact the company's production and future launch plans.

The company is also likely to take a revenue hit as the company will not be able to sell the EV charger separately and will have to bundle it in the cost of the scooter, to comply with FAME norms. However, the senior executive said that it will take a few months for the company to assess the impact of not being able to sell the charger separately and factoring the price in the overall cost of the vehicle.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Allianz, BlackRock and T&D in consortium for Cinven's Viridium stake
Allianz, BlackRock and T&D in consortium for Cinven's Viridium stake
Mar 19, 2025
FRANKFURT, March 19 (Reuters) - A consortium that includes Allianz, BlackRock ( BLK ) and T&D Holdings ( TDHOF ) are investing in Viridium Group in a 3.5 billion euro ($3.82 billion) deal that will see the private equity company Cinven exit as a majority investor, Allianz said on Wednesday. Viridium is a company that specializes in buying existing life...
Top Premarket Gainers
Top Premarket Gainers
Mar 19, 2025
07:46 AM EDT, 03/19/2025 (MT Newswires) -- Leishen Energy Holding ( LSE ) shares soared 94% pre-bell Wednesday, extending Tuesday's rally. MediWound ( MDWD ) shares were up 19% after the company reported higher Q4 revenue. Cargo Therapeutics ( CRGX ) shares jumped 18%, a day after the company said it will reduce its workforce by about 90% to preserve...
Ollie's Bargain Outlet Fiscal Q4 Adjusted Net Income Falls, Net Sales Rise
Ollie's Bargain Outlet Fiscal Q4 Adjusted Net Income Falls, Net Sales Rise
Mar 19, 2025
07:47 AM EDT, 03/19/2025 (MT Newswires) -- Ollie's Bargain Outlet (OLLI) reported fiscal Q4 adjusted net income Wednesday of $1.19 per diluted share, down from $1.23 a year earlier. Analysts polled by FactSet expected $1.19. Net sales for the quarter ended Feb. 1 were $667.1 million, compared with $648.9 million a year earlier. Analysts surveyed by FactSet expected $675.4 million....
Merck Says Canada Approves Keytruda Combo for Advanced Uterine Cancer
Merck Says Canada Approves Keytruda Combo for Advanced Uterine Cancer
Mar 19, 2025
07:47 AM EDT, 03/19/2025 (MT Newswires) -- Merck ( MRK ) said Wednesday that Health Canada has approved Keytruda combined with chemotherapy for adults with advanced or recurrent endometrial cancer. The decision is based on the results of a late-stage trial that showed Keytruda combined with carboplatin and paclitaxel helped delay disease progression in both major patient groups with mismatch...
Copyright 2023-2026 - www.financetom.com All Rights Reserved